Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

BCYC 11.25.2024

Full Press ReleaseSEC FilingsOur BCYC Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
  • 01.09.2025 - Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 01.06.2025 - 4 Statement of changes in beneficial ownership of securities

Abstract outlines data showing enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer patients with NECTIN4 gene amplification

Company to announce topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer

Conference call and webcast scheduled forFriday, Dec. 13, at7 a.m. CTto review all data

CAMBRIDGE, England&BOSTON--(BUSINESS WIRE)--Nov. 25, 2024--Bicycle Therapeutics plc(NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer (TNBC) patients withNECTIN4gene amplification at the 2024 San Antonio Breast Cancer Symposium (SABCS) taking placeDecember 10-13inSan Antonio, Texas.

In conjunction with the SABCS poster presentation,Bicycle Therapeuticswill also announce topline combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer, and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer patients withNECTIN4gene amplification. The company will host a conference call and webcast for analysts and investors to review the updated data for zelenectide pevedotin.

Poster Presentation:Title:Enhanced anti-tumor activity of zelenectide pevedotin in triple negative breast cancer (TNBC) patients (pts) withNECTIN4gene amplification (amp)Session Number:4Date and Time:Thursday, Dec. 12, at5:30-7 p.m. CTPresentation Number:P4-10-21Lead Author:Niklas Klümper, M.D., University Hospital Bonn

Conference Call and Webcast InformationBicycle Therapeuticswill host a conference call and webcast onFriday, Dec. 13, at7 a.m. CTto review the data updates for zelenectide pevedotin. To access the call, please dial +1-833-816-1408 (U.S.) or +1-412-317-0501 (international) and ask to join theBicycle Therapeuticscall. A live webcast and replay of the conference call will be available in the Investor section of the company’s website,www.bicycletherapeutics.com.

AboutBicycle TherapeuticsBicycle Therapeuticsis a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.

Bicycle Therapeuticsis headquartered inCambridge, UK, with many key functions and members of its leadership team located inCambridge, Mass.For more information, visitbicycletherapeutics.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241125297563/en/

Investors:Stephanie YaoSVP, Investor Relations and Corporate Communicationsstephanie.yao@bicycletx.com857-523-8544Matthew DeYoungArgot Partnersir@bicycletx.com212-600-1902Media:Jim O’ConnellWeber Shandwickmedia@bicycletx.com312-988-2343

Source:Bicycle Therapeutics plc

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com